Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP InhibitorsIn VitroandIn Vivo.
Siemeister, G., Mengel, A., Fernandez-Montalvan, A.E., Bone, W., Schroder, J., Zitzmann-Kolbe, S., Briem, H., Prechtl, S., Holton, S.J., Monning, U., von Ahsen, O., Johanssen, S., Cleve, A., Putter, V., Hitchcock, M., von Nussbaum, F., Brands, M., Ziegelbauer, K., Mumberg, D.(2019) Clin Cancer Res 25: 1404-1414
- PubMed: 30429199 
- DOI: https://doi.org/10.1158/1078-0432.CCR-18-0628
- Primary Citation of Related Structures:  
6F7B - PubMed Abstract: 
The catalytic function of BUB1 is required for chromosome arm resolution and positioning of the chromosomal passenger complex for resolution of spindle attachment errors and plays only a minor role in spindle assembly checkpoint activation. Here, we present the identification and preclinical pharmacologic profile of the first BUB1 kinase inhibitor with good bioavailability.
Organizational Affiliation: 
Bayer AG, Muellerstrasse Berlin, Germany. gerhard.siemeister@bayer.com.